Escalation of radiotherapy dose in large locally advanced drug-resistant gastrointestinal stromal tumors by multi-shell simultaneous integrated boost intensity-modulated technique: a feasibility study

Table 1 Patient, tumor, and treatment characteristics

No	Age (Diagnosis/RT)	Primary tumor site	Type of resection	Genetic mutation	TKIs therapy	Indication for RT	Tumor size before RT
1	62/67	Small intestine	R₀	NA	Imatinib 24 M /sunitinib 36 M	Progression on TKIs resistance and unresectable	18.0 cm
2	50/55	Jejunum	R₀	C-kit(E11)p.L576P, C-kit(E13)p.V654A	Imatinib 32 M /sunitinib 12 M/regorafenib 6 M	Progression on TKIs resistance and unresectable	17.2 cm
3	56/60	Ileum	R₀	NA	Sunitinib 42 M	Progression on TKIs resistance and unresectable	20.0 cm
4	50/51	Duodenum	R₀	NA	Imatinib 4 M/sunitinib 5 M	Progression on TKIs resistance and unresectable	12.0 cm
5	51/58	Jejunum	R₀	C-kit(E11), C-kit(E17)p.Y823D	Imatinib 78 M/sunitinib 9 M	Progression on TKIs resistance and unresectable	17.0 cm
6	57/60	Small intestine	R₀	NA	Imatinib 21 M/sunitinib 18 M	Progression on TKIs resistance and unresectable	14.5 cm
7	39/49	Small intestine	R₀	C-kit(E17)p.N822K	Imatinib 55 M/sunitinib 26 M/regorafenib 2 M	Progression on TKIs resistance and unresectable	16.5 cm

No.: patient number; R0: microscopically margin-negative resection. M: the length of time (months) that patients take TKIs. Tumor size before RT: the maximum diameter of tumor in the diagnostic CT imaging

ISSN: 1748-717X